Caplin Point Laboratories Ltd.
CAPLIPOINT · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,365.82.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%19.9%
- ✓Low debt (D/E < 0.5)0.00x
- ✓Positive free cash flow
- ✓Revenue growth > 10%19%
- ✓Earnings growing19%
- ✓Net margin ≥ 10%29.3%
- ✓Current ratio > 1.56.70
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 27.88
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (19.9%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (29.3%).
- •Trading near its 52-week high.
- •Financially solid — Altman Z 27.88.
Weaknesses
- •Weak Piotroski score (3/9).
Opportunities
- •Earnings growing (19% YoY).
- •Revenue growing (19% YoY).
- •Trading in our value buy zone versus sector peers.
Threats
- •Trades ~28% above our estimated fair value.
About Caplin Point Laboratories Ltd.
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.